Therefore, further research directed at the identification of PARPi response-specific TP53 mutations in the CRC cohorts may help clarify the roles of TP53 mutations in PARPi response and improve the performance of TP53 mutation status in predicting PARPi response in CRC. Here, TP53 is linked to colorectal carcinoma.